CON — Concentra Group Holdings Parent, Inc. stock price, charts and financials
QT74Concentra Group Holdings Parent, Inc.Concentra Group Holdings Parent, Inc. (NYSE: CON) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 22.55 | EPS (ttm) | 1.38 | Insider Own | 6.16% | Shs Outstand | 127.96M | Perf Week | -4.80% |
| Market Cap | 3.98B | Forward P/E | 18.41 | EPS next Y | 1.69 | Insider Trans | -4.95% | Shs Float | 114.50M | Perf Month | -2.26% |
| Enterprise Value | 6.04B | PEG | 2.04 | EPS next Q | - | Inst Own | - | Short Float | 2.95% | Perf Quarter | 37.27% |
| Income | 178.00M | P/S | 1.78 | EPS this Y | 9.70% | Inst Trans | - | Short Ratio | 3.70 | Perf Half Y | 40.50% |
| Sales | 2.23B | P/B | 8.77 | EPS next Y | 11.67% | ROA | 6.16% | Short Interest | 3.38M | Perf YTD | 58.13% |
| Book/sh | 3.55 | P/C | 64.23 | EPS next 5Y | 11.08% | ROE | 46.05% | 52W High | 32.86 -5.30% | Perf Year | 59.75% |
| Cash/sh | 0.48 | P/FCF | 13.81 | EPS past 3/5Y | -0.51% - | ROIC | 60.75% | 52W Low | 18.55 67.76% | Perf 3Y | - |
| Dividend Est. | 0.25 (0.80%) | EV/EBITDA | 14.02 | Sales past 3/5Y | 7.85% - | Gross Margin | 27.79% | Volatility | 2.54% 2.49% | Perf 5Y | - |
| Dividend TTM | 0.25 (0.80%) | EV/Sales | 2.71 | EPS Y/Y TTM | 6.15% | Oper. Margin | 94.26% | ATR (14) | 0.84 | Perf 10Y | - |
| Dividend Ex-Date | May 19, 2026 | Quick Ratio | 1.26 | Sales Y/Y TTM | 17.53% | Profit Margin | 7.97% | RSI (14) | 52.60 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.26 | EPS Q/Q | 25.00% | SMA20 | -1.25% | Beta | 0.44 | Target Price | 33.00 |
| Payout | 4.50% | Debt/Eq | 5.00 | Sales Q/Q | 13.77% | SMA50 | 6.48% | Rel Volume | 0.77 | Prev Close | 31.70 |
| Employees | 13,133 | LT Debt/Eq | 4.78 | Earnings | Aug 06 | SMA200 | 32.18% | Avg Volume | 965.49K | Price | 31.12 |
| IPO Date | May 25, 2010 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 18.30% 2.90% | Net Debt/EBITDA | 4.79 | Volume | 741,043 | Change | -1.83% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-14-26 | Reiterated | Truist Securities | Buy | $29 → $37 |
| Jun-05-26 | Reiterated | Goldman Sachs | Buy | $26 → $30 |
| May-08-26 | Reiterated | Deutsche Bank | $29 → $32 | |
| Feb-02-26 | Reiterated | RBC Capital | Outperform | $31 |
| Oct-14-25 | Reiterated | UBS | $38 → $52 | |
| Mar-06-25 | Reiterated | Goldman Sachs | $24 → $26 | |
| Dec-16-24 | Upgrade | B of A Securities | Neutral → Buy | |
| Oct-07-24 | Downgrade | B of A Securities | Buy → Neutral | |
| Aug-19-24 | Initiated | Deutsche Bank | $29 | |
| Aug-19-24 | Initiated | BofA | Buy | $31 |
Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions. The company delivers a comprehensive suite of occupational and consumer health services, encompassing treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific programs, along with wellness initiatives. These services are accessible through their network of occupational health centers and onsite clinics. Furthermore, Concentra offers specialized solutions like Concentra Telemed, a telemedicine platform for addressing work-related injuries and illnesses and supporting employer services; Concentra Pharmacy, providing pharmaceutical solutions; and Concentra Medical Compliance Administration, a third-party administrative service that assists employers in managing drug abuse testing programs for both regulated and non-regulated workforces. Established in 1979 and headquartered in Mechanicsburg, Pennsylvania, the company functions as a subsidiary of Select Medical Corporation.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 2,233 | 2,163 | 1,900 | 1,838 | 1,724 | 1,732 | |
| Cost of Goods Sold Incl. D&A | 1,612 | 1,550 | 1,372 | 1,326 | 1,316 | 1,304 | |
| Gross Profit | 620 | 613 | 528 | 512 | 408 | 428 | |
| Selling, General and Administrative Excl. Other | 210 | 203 | 156 | 152 | 150 | 158 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | -1,694 | -1,678 | 67 | 73 | 0 | 0 | |
| Operating Income | 2,104 | 2,088 | 305 | 288 | 258 | 270 | |
| Interest Expense | 111 | 109 | 70 | 114 | 32 | 32 | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1,755 | -1,755 | -4 | 69 | -2 | 37 | |
| Net Income Before Taxes | 240 | 224 | 231 | 243 | 225 | 276 | |
| Income Taxes | 55 | 51 | 59 | 58 | 53 | 60 | |
| Consolidated Net Income | 178 | 173 | 167 | 180 | 167 | 209 | |
| Net Income From Continuing Operations | 184 | 173 | 172 | 185 | 172 | 216 | |
| Net Income | 178 | 173 | 167 | 180 | 167 | 209 | |
| EPS (Recurring) | 1.39 | 1.39 | 1.30 | 1.42 | 1.32 | 1.65 | |
| EPS (Basic, Before Extraordinaries) | 1.39 | 1.39 | 1.30 | 1.42 | 1.32 | 1.65 | |
| EPS (Diluted) | 1.38 | 1.30 | 1.30 | 1.42 | 1.32 | 1.65 | |
| EBITDA | 431 | 409 | 368 | 360 | 330 | 390 | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | 22.55 | 15.14 | 15.22 | — | — | — | |
| Price To Sales Ratio | 1.77 | 1.16 | 1.33 | — | — | — | |
| Gross Margin | 27.77 | 28.34 | 27.79 | 27.86 | 23.67 | 24.71 | |
| Operating Margin | 94.22 | 96.53 | 16.05 | 15.67 | 14.97 | 15.59 | |
| Net Margin | 7.97 | 8.00 | 8.79 | 9.79 | 9.69 | 12.07 | |
| Shares Outstanding | 127 | 127 | 128 | 127 | 127 | 127 | |
| Market Capitalization | 3,952 | 2,499 | 2,532 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ORTENZIO ROBERT A | Director | Jul 01 '26 | Sale | 30.50 | 130,000 | 3,964,597 | 633,455 | Jul 06 |
| ORTENZIO ROBERT A | Director | Jun 01 '26 | Sale | 25.00 | 130,000 | 3,250,026 | 763,455 | Jun 02 |
| ORTENZIO ROBERT A | Director | May 08 '26 | Sale | 25.00 | 130,000 | 3,250,000 | 893,455 | May 11 |